| Texto completo | |
| Autor(es): |
Milani, Thamires M. S.
;
Sandy, Camila M.
;
Carvalho Thiers Calazans, Ana Paula
;
Silva, Rosana Q.
;
Fonseca, Vanessa M. B.
;
Martins, Flaviano S.
;
Borges, Marcos C.
Número total de Autores: 7
|
| Tipo de documento: | Artigo Científico |
| Fonte: | PROBIOTICS AND ANTIMICROBIAL PROTEINS; v. N/A, p. 9-pg., 2022-11-29. |
| Resumo | |
Probiotics should be administered in adequate amounts to confer health benefits. Probiotic dose-response studies are still missing. Saccharomyces cerevisiae UFMG A-905 prevented asthma development; however, the ideal dose has not been investigated. We evaluated the optimal dose and administration regimen of S. cerevisiae UFMG A-905 in the prevention of asthma. Male Balb/c mice were sensitized intraperitoneally with ovalbumin (OVA) and challenged with OVA intranasally. Mice received, via gavage, daily or alternate-day S. cerevisiae UFMG A-905. In daily regimen, different concentrations (10(7), 10(8), or 10(9) CFU/mL) were given 10 days before OVA sensitization and during challenges. In alternate-day regimen, a concentration of 10(9) CFU/mL was administered three times per week for 5 weeks, starting 2 weeks prior to the first sensitization. After the last challenge, in vivo bronchial hyperresponsiveness and airway and lung inflammation were assessed. OVA-challenged mice, when compared to saline-challenged mice, presented a significant increase in bronchial hyperresponsiveness and airway and lung inflammation. Daily and alternate-day administration of 10(9) CFU/mL of S. cerevisiae UFMG A-905 significantly reduced bronchial hyperresponsiveness; lower concentrations of S. cerevisiae UFMG A-905 did not significantly reduce bronchial hyperresponsiveness. Daily regimen with the highest concentration significantly reduced total cell number, eosinophil count in the BAL, and the levels of IL-4, IL-5, and IL-13. Daily administration of S. cerevisiae UFMG A-905 at 10(7) and 10(8) CFU/mL and alternate-day regimen did not significantly decrease airway and lung inflammation. S. cerevisiae UFMG A-905 led to a significant attenuation of bronchial hyperresponsiveness and lung inflammation in a dose-dependent manner. (AU) | |
| Processo FAPESP: | 10/20600-4 - Estudo da prevenção e tratamento da asma induzida por alérgeno em um modelo animal com a administração de Saccharomyces cerevisiae vivas e inativadas pelo calor |
| Beneficiário: | Marcos de Carvalho Borges |
| Modalidade de apoio: | Auxílio à Pesquisa - Jovens Pesquisadores |